Denali Therapeutics Inc. $DNLI Position Raised by Invesco Ltd.

Key Points

• Invesco Ltd. increased its stake in Denali Therapeutics Inc. by 55.9% in Q1, acquiring an additional 67,949 shares, bringing its total ownership to 189,427 shares valued at approximately $2.57 million.
• Multiple institutional investors have also raised their holdings in Denali Therapeutics, with total institutional ownership now at 92.92%.
• Denali Therapeutics reported a quarterly EPS of ($0.72), slightly outperforming analysts' expectations, but the stock has seen a 2.4% decline recently and currently holds a market cap of $2.23 billion.

Invesco Ltd. lifted its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 55.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 189,427 shares of the company's stock after buying an additional 67,949 shares during the quarter. Invesco Ltd. owned about 0.13% of Denali Therapeutics worth $2,575,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. GF Fund Management CO. LTD. acquired a new position in Denali Therapeutics in the 4th quarter valued at $62,000. Point72 Hong Kong Ltd acquired a new position in Denali Therapeutics in the 4th quarter valued at $65,000. GAMMA Investing LLC increased its stake in Denali Therapeutics by 253.8% in the 1st quarter. GAMMA Investing LLC now owns 7,953 shares of the company's stock valued at $108,000 after buying an additional 5,705 shares during the period. Tower Research Capital LLC TRC increased its stake in Denali Therapeutics by 2,519.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 11,288 shares of the company's stock valued at $230,000 after buying an additional 10,857 shares during the period. Finally, Breakwater Capital Group acquired a new position in Denali Therapeutics in the 1st quarter valued at $204,000. Hedge funds and other institutional investors own 92.92% of the company's stock.

Insider Transactions at Denali Therapeutics

In other news, insider Carole Ho sold 2,937 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total transaction of $39,884.46. Following the completion of the sale, the insider owned 217,391 shares of the company's stock, valued at approximately $2,952,169.78. This trade represents a 1.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Alexander O. Schuth sold 2,937 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total value of $39,884.46. Following the transaction, the insider owned 242,346 shares in the company, valued at $3,291,058.68. This trade represents a 1.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 501,962 shares of company stock valued at $7,520,799. 12.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on DNLI shares. TD Cowen raised shares of Denali Therapeutics to a "strong-buy" rating in a research note on Monday, July 28th. Wedbush lowered their price objective on shares of Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Robert W. Baird reduced their target price on shares of Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating on the stock in a report on Thursday, May 8th. Bank of America reduced their target price on shares of Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Finally, HC Wainwright cut their price objective on shares of Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, Denali Therapeutics has a consensus rating of "Buy" and a consensus target price of $33.62.

Denali Therapeutics Stock Down 3.4%

NASDAQ:DNLI traded down $0.52 during trading hours on Thursday, hitting $14.79. The stock had a trading volume of 1,331,493 shares, compared to its average volume of 1,872,721. The company has a current ratio of 10.27, a quick ratio of 10.27 and a debt-to-equity ratio of 0.01. Denali Therapeutics Inc. has a 1-year low of $10.57 and a 1-year high of $33.33. The business has a 50 day simple moving average of $14.52 and a two-hundred day simple moving average of $14.70. The company has a market cap of $2.16 billion, a PE ratio of -5.28 and a beta of 1.23.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.02. During the same quarter last year, the company posted ($0.59) earnings per share. Analysts predict that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.